Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Vanderbilt research indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.